|
|
Article: Studies from Groningen University describe new findings in enzyme research.
- Article from:
- Blood Weekly
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"C-13-urea may be a suitable marker to assess the in vivo fate of colon-targeted dosage forms given by mouth. We postulated that release in the colon (urease-rich segment) of C-13-urea from colon-targeted capsules would lead to fermentation of C-13-urea by bacterial ureases into (CO2)-C-13," investigators in Netherlands report (see also Enzyme Research).
"Subsequent absorption into the blood and circulation would lead to detectable C-13 (as (CO2)-C-13) in breath. If, however, release of C-13-urea occurred in the small intestine (urease-poor segment), we expected detectable C-13 (as C-13-urea) in blood but no breath C-13 (as (CO2)-C-13). The differential kinetics ...
Related newspaper, magazine, and journal articles:
|
|
Article: Data from Groningen University advance knowledge in ...
Cancer Weekly;
November 25, 2008 ;
700+ words
... ... and colleagues, Groningen University (see also Cancer ... A. Gietema, Groningen University Medical Center ... Therapy, Drugs, Enzyme Research, Etoposide ... Treatment, Groningen University. This article ...
|
|